Skip to main content

Quest Diagnostics Value Stock - Dividend - Research Selection

Quest diagnostics

ISIN: US74834L1008 , WKN: 904533

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company\'s Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. Its Diagnostic Solutions segment offers risk assessment services for the life insurance industry; and health information technology solutions for healthcare organizations and clinicians. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


All You Need to Know About Quest Diagnostics (DGX) Rating Upgrade to Buy

2024-11-13
Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Cardinal Health Stock Gains Following Two Strategic Acquisitions

2024-11-13
CAH announces two strategic acquisitions to strengthen its multi-specialty and at-Home Solutions businesses.

Alcon Q3 Earnings Top Estimates, Margins Up, Stock Gains in Afterhours

2024-11-13
ALC's performance is driven by robust demand for the company's innovative products, balanced geographic footprint and strong execution by the team.

Is Quest Diagnostics Stock a Smart Addition to Your Portfolio Now?

2024-11-13
DGX exhibits strength in its base business. Increasing utilization of the Advanced Diagnostics offering is another positive.

Quest Diagnostics Declares Quarterly Cash Dividend

2024-11-12
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.75 per share, payable on January 29, 2025 to shareholders of record of Quest Diagnostics common stock on January 14, 2025.

Integer Holdings Gains 40.8% YTD: What's Driving the Stock?

2024-11-12
ITGR shares gain on the back of growth in the Medical segment. However, fluctuations in the oil and energy market are concerning.

Nevro Stock Rises on Q3 Earnings Beat, Revenues Decrease Y/Y

2024-11-12
NVRO's third-quarter earnings beat its Zacks Consensus Estimate, while worldwide revenues decline year over year. The company continues to incur losses at the operating level.

PODD Stock Gains on Q3 Earnings and Revenue Beat, '24 Sales View Up

2024-11-12
Insulet's third-quarter performance benefits from the continued high demand for Omnipod 5.

DGX vs. PNTG: Which Stock Is the Better Value Option?

2024-11-11
DGX vs. PNTG: Which Stock Is the Better Value Option?

INGN Stock Gains Following Q3 Earnings Beat, Adjusted Gross Margin Up

2024-11-11
Inogen's overall third-quarter 2024 results continue to gain from higher business-to-business sales.